Lomefloxacin Hydrochloride

DescriptionLomefloxacin is an orally bioavailable, broad-spectrum fluoroquinolone antibiotic. In vitro, it inhibits growth of N. gonorrhoeae, E. coli, K. pneumoniae, P. vulgaris, S. epidermidis, and M. morganii (MIC90s = 0.1, 0.39, 0.39, 0.39, 0.39, and 0.78 μg/ml, respectively). It also inhibits growth of S. aureus and methicillin-resistant S. aureus (MRSA; MIC90 = 3.13 μg/ml for both) and of H. influenzae and ampicillin-resistant H. influenzae (MIC90 = 0.1 μg/ml for both). In vivo, lomefloxacin inhibits the growth of P. mirabilis, E. coli, K. pneumoniae, and S. aureus (ED50s = 1.39, 1.45, 1.78, and 6.66 mg/kg, respectively) in mouse models of systemic infection. It inhibits bacterial DNA gyrase, thereby inhibiting DNA synthesis and bacterial growth. Formulations containing lomefloxacin have been used in the treatment of bronchitis and urinary tract bacterial infections.

DescriptionLomefloxacin hydrochloride is the hydrochloride form of Lomefloxacin. Lomefloxacin is a bactericidal fluoroquinolone agent that is active against gram-negative and gram-positive organisms. Lomefloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, which are needed for the transcription and replication of bacterial DNA. DNA gyrase is thought to be the primary quinolone target for gram-negative bacteria. Topoisomerase IV is thought to be the primary target in gram-positive organisms. The inhibition of the topoisomerases results in strand breakage of the bacterial chromosome, supercoiling, and resealing. Therefore, DNA replication and transcription is inhibited. Lomefloxacin can be used to treat many kinds of infections such as respiratory, urinary tract, obstetric, gynaecological, joint, skin, oral, ear, nose, throat and eye infections. Compared with other quinolone antibacterial drugs, lomefloxacin has certain advantages such as convenient administration and no necessity of theophylline dosage adjustment.